Acquisition of Separation Technology, Inc.
12 March 2014
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Acquisition of Separation Technology, Inc.
EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, announces that it has acquired Separation Technology, Inc. ("STI"), the Florida based manufacturer of in vitro diagnostics ("IVD") devices for the haematology testing market for a cash consideration of $4.0m (c. £2.4m) to be satisfied out of current debt facilities. The acquisition of STI is expected to be earnings enhancing in 2014 and complements the Company's existing offering in the haemoglobin testing market place.
About Separation Technology, Inc.
STI develops, manufactures and markets specialty IVD devices including ultrasound instruments and table top centrifuges for the haematology testing market. STI also has an in-house engineering capability, including product design, production support and new product development. STI's revenues are currently concentrated in the US market (92% in 2013), however the business has sought to expand its offering into markets outside of the US and has recently registered products in Brazil (UltraCrit) as well as Kazakhstan, Russia and Thailand. STI currently employs 15 staff, is based in Sanford, Florida, USA, and is being sold by Thermo Fisher Scientific Inc.
STI's primary instrument is the ultrasound based UltraCrit haematocrit measurement device, which is FDA cleared for blood donor screening. The haematocrit reading is displayed automatically in about 30 seconds and provides a haematocrit value that allows for standardisation for all collections, including whole blood, apheresis and double red cell collections. UltraCrit uses reagentless cuvettes, a major point of differentiation between different analysers, given the relatively high cost of reagents in high-volume haematology testing. STI also manufactures a range of centrifuges including HemataStat, also used for haematocrit reading.
STI's revenue for the year ended 31 December 2013 was approximately $4.0m and EBITDA was approximately $0.5m. STI had net assets of approximately $1.0m at 31 December 2013. For more information: www.separationtechnology.com
Julian Baines, CEO of EKF commented: "The acquisition of STI is a great natural fit with our existing Point-of-care business, and UltraCrit provides us with a leading product for measuring haematocrit during blood donor screening with huge potential. The acquisition has been funded from our own resources and we expect it to be earnings enhancing from day one; so I am very confident that this acquisition represents a good value opportunity for EKF shareholders."
Enquiries:
|
EKF Diagnostics Holdings plc |
Tel: 029 2071 0570 |
|
David Evans, Executive Chairman |
Mob: 07740 084 452 |
|
Julian Baines, CEO |
Mob: 07788 420 859 |
|
|
|
|
Canaccord Genuity Limited |
Tel: 020 7523 8000 |
|
Lucy Tilley / Julian Feneley / Henry Fitzgerald-O'Connor |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 |
|
Paul McManus |
Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
|
Paul Cornelius |
Mob: 07866 384 707 or paul.cornelius@walbrookir.com |
About EKF Diagnostics Holdings plc
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of glucose, lactate, haemoglobin, haematocrit and HbA1c.
In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived HemoControl device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.
For more information please visit the website: www.ekfdiagnostics.com
This information is provided by RNS
Latest directors dealings
- 51 minutes ago Frasers Group
- 51 minutes ago Cavendish Financial
- 51 minutes ago Diaceutics
- 51 minutes ago AB Dynamics
- 14 hours ago Johnson Matthey